MEHREEN S KHAN

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology HOUSTON, TX NPI 1457562399

General Payments — all program years on this page

$1,754.91

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 81
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $427.41 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $427.4119

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $184.8111
2019 $110.435
2020 $78.093
2021 $259.4811
2022 $337.0115
2023 $357.6817
2024 $427.4119

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086143611 Bayer Healthcare Pharmaceuticals Inc. $24.28 02/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086208713 Bayer Healthcare Pharmaceuticals Inc. $26.29 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086221479 Bayer Healthcare Pharmaceuticals Inc. $19.62 06/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086254758 Bayer Healthcare Pharmaceuticals Inc. $22.51 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087117914 Novartis Pharmaceuticals Corporation $29.14 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087117936 Novartis Pharmaceuticals Corporation $31.04 10/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097550334 Novo Nordisk Inc $17.59 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104222951 AstraZeneca Pharmaceuticals LP $21.71 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104292112 AstraZeneca Pharmaceuticals LP $24.90 06/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105535484 AstraZeneca Pharmaceuticals LP $24.40 01/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105619073 AstraZeneca Pharmaceuticals LP $22.60 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105855980 AstraZeneca Pharmaceuticals LP $24.40 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117296278 Amgen Inc. $16.83 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118017223 Boehringer Ingelheim Pharmaceuticals, Inc. $22.80 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1127037342 Kyowa Kirin, Inc. $18.16 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135199625 Lilly USA, LLC $20.99 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141527710 CALLIDITAS THERAPEUTICS US INC. $15.41 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145092763 Mallinckrodt Hospital Products Inc. $27.43 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149949749 Travere Therapeutics, Inc. $17.31 07/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.